105 DIGITAL DRIVE, NOVATO, CA
BioMarin Pharmaceutical Acquires Alesta Therapeutics for $283 Million IPR&D
BioMarin Enters Settlement and License Agreement with Ascendis Pharma
Other Events
Board Expansion - Robert Plenge Appointed as New Director
Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties on Yuviwel Sales in U.S., EU, Brazil and South Korea
To Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Pipeline
Amended material disclosure
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Third Party
Correspondence